ClinicalTrials.gg
CompletedNCT00690573Updated Sep 10, 2012Results posted

Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

A Phase 3 interventional study of Adalimumab in Juvenile Rheumatoid Arthritis, sponsored by Abbott. Completed at 12 sites in Japan. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2012-09-10.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies in Arthritis, Juvenile with a site in Japan — 3 open to participants now, 6 under way, 5 of them phase 3. Arthritis, Juvenile · Japan.

Enrollment
8th of 11
25 · median 58
Started
2008
the only one that year
Phase 3
10 of 12
3 open now
Registered
1st of 12
by date
Lead sponsor
1 of 12
Abbott

Among the 12 studies in Arthritis, Juvenile with a site in Japan, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2008, is one of 10 in phase 3, and was the 1st registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

3 of the 12 studies in Arthritis, Juvenile with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arthritis, Juvenile with a site in Japan, or all of them as a file.
02

Study summary

To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese children with Polyarticular Juvenile Rheumatoid Arthritis

Read the detailed description

This was an open-label long-term study that was completed following study drug approval in Japan for the treatment of JRA. Data are presented through Week 144 and for the final visit.

03

Conditions studied

  • Juvenile Rheumatoid Arthritis

Browse trials for

Keywords

  • Juvenile Rheumatoid Arthritis
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of polyarticular juvenile rheumatoid arthritis (JRA) according to the criteria of the American College on Rheumatology (ACR)
  • Disease activity inadequately controlled by nonsteroidal anti-inflammatory drugs (NSAIDs) or methotrexate (MTX)
  • Presence at screening of at least 5 swollen joints (not due to deformity) and at least 3 joints with limitation of passive motion with pain by passive motion or/and pain by pressure (tenderness)
  • Stable dosage of MTX for at least 12 weeks prior to the screening visit or discontinuation of MTX at least 14 days prior to baseline visit (Day 1)
  • Discontinuation of disease-modifying antirheumatic drugs (DMARDs) other than MTX at least 28 days before screening visit

Exclusion criteria

Exclusion Criteria

  • History of inflammatory joint disease other than JRA
  • Functional class IV JRA by ACR criteria
  • cardiac disease or laboratory abnormalities
  • Any subject who is considered by the investigator, for any reason, to be an unsuitable candidate for the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).

    Also known as: adalimumab, ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16

    Response defined as at least 30% improvement in 3 or more of 6 juvenile rheumatoid arthritis (JRA) core set criteria, and at least 30% worsening in not more than 1 JRA criterion, compared with baseline. JRA core set criteria include physician's global assessment of disease severity; parent's/patient's global assessment of overall well-being; number of active joints (joints with swelling or with limitation of motion \[LOM\] and with pain, tenderness or both); number of joints with LOM; physical function of the Disability Index of Childhood Health Assessment Questionnaire; C-reactive protein.

    Time frame: Week 16

Secondary outcomes

  1. Number of Subjects Achieving PedACR50 and PedACR70 Responses at Week 16

    Response defined as at least 50/70% improvement in 3 or more of 6 juvenile rheumatoid arthritis (JRA) core set criteria, and at least 50/70% worsening in not more than 1 JRA criterion compared with baseline. JRA core set criteria include physician's global assessment of disease severity; parent's/patient's global assessment of overall well-being; number of active joints (joints with swelling or with limitation of motion \[LOM\] and with pain, tenderness or both); number of joints with LOM; physical function of the Disability Index of Childhood Health Assessment Questionnaire; C-reactive protein.

    Time frame: Week 16

  2. Number of Subjects Achieving PedACR 30/50/70 Responses

    Time frame: Week 2, 4, 8, and 24, every 12 weeks from Week 24 to Week 60, and every 24 weeks from Week 72 to the final visit

  3. Mean Serum Adalimumab Concentration

    Blood samples were drawn prior to drug administration. Adalimumab concentrations in serum were determined using a validated enzyme-linked immunosorbent assay (ELISA) method based on a double-antigen technique. Concentrations are reported as micrograms per milliliter (mcg/mL).

    Time frame: Week 2, 4, 8, 16, and 24, and every 12 weeks up to Week 60

  4. Number of Subjects Positive for Anti-adalimumab Antibodies (AAA)

    Serum samples with adalimumab concentration below 2 mcg/mL were selected for AAA analyses. Samples were considered AAA positive if the measured AAA concentration was above 20 ng/mL. A subject was considered to be AAA positive if the subject had at least one AAA positive sample observed within 30 days following the subject's last adalimumab dose.

    Time frame: Week 24 and Week 60

07

Results

Posted Apr 1, 2011

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab
Started25
Completed16
Not completed9
Withdrew: Lack of efficacy8
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16

Response defined as at least 30% improvement in 3 or more of 6 juvenile rheumatoid arthritis (JRA) core set criteria, and at least 30% worsening in not more than 1 JRA criterion, compared with baseline. JRA core set criteria include physician's global assessment of disease severity; parent's/patient's global assessment of overall well-being; number of active joints (joints with swelling or with limitation of motion \[LOM\] and with pain, tenderness or both); number of joints with LOM; physical function of the Disability Index of Childhood Health Assessment Questionnaire; C-reactive protein.

Time frame:
Week 16
Reported as:
Number · Participants
Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16
ParticipantsAdalimumab
Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 1623
SecondaryNumber of Subjects Achieving PedACR50 and PedACR70 Responses at Week 16

Response defined as at least 50/70% improvement in 3 or more of 6 juvenile rheumatoid arthritis (JRA) core set criteria, and at least 50/70% worsening in not more than 1 JRA criterion compared with baseline. JRA core set criteria include physician's global assessment of disease severity; parent's/patient's global assessment of overall well-being; number of active joints (joints with swelling or with limitation of motion \[LOM\] and with pain, tenderness or both); number of joints with LOM; physical function of the Disability Index of Childhood Health Assessment Questionnaire; C-reactive protein.

Time frame:
Week 16
Reported as:
Number · Participants
Number of Subjects Achieving PedACR50 and PedACR70 Responses at Week 16
ParticipantsAdalimumab
Number of Subjects Achieving PedACR50 at Week 1622
Number of Subjects Achieving PedACR70 at Week 1615
SecondaryNumber of Subjects Achieving PedACR 30/50/70 Responses
Time frame:
Week 2, 4, 8, and 24, every 12 weeks from Week 24 to Week 60, and every 24 weeks from Week 72 to the final visit
Reported as:
Number · Participants
Number of Subjects Achieving PedACR 30/50/70 Responses
ParticipantsAdalimumab
Number of subjects achieving PedACR30 at Week 215
Number of subjects achieving PedACR30 at Week 416
Number of subjects achieving PedACR30 at Week 819
Number of subjects achieving PedACR30 at Week 2421
Number of subjects achieving PedACR30 at Week 3622
Number of subjects achieving PedACR30 at Week 4821
Number of subjects achieving PedACR30 at Week 6020
Number of subjects achieving PedACR30 at Week 7219
Number of subjects achieving PedACR30 at Week 9618
Number of subjects achieving PedACR30 at Week 12011
Number of subjects achieving PedACR30 at Week 1445
Number of subjects achieving PedACR30- Final Visit22
Number of subjects achieving PedACR50 at Week 27
Number of subjects achieving PedACR50 at Week 413
Number of subjects achieving PedACR50 at Week 815
Number of subjects achieving PedACR50 at Week 2419
Number of subjects achieving PedACR50 at Week 3622
Number of subjects achieving PedACR50 at Week 4819
Number of subjects achieving PedACR50 at Week 6020
Number of subjects achieving PedACR50 at Week 7218
Number of subjects achieving PedACR50 at Week 9618
Number of subjects achieving PedACR50 at Week 12011
Number of subjects achieving PedACR50 at Week 1445
Number of subjects achieving PedACR50- Final Visit20
Number of subjects achieving PedACR70 at Week 21
Number of subjects achieving PedACR70 at Week 47
Number of subjects achieving PedACR70 at Week 88
Number of subjects achieving PedACR70 at Week 2415
Number of subjects achieving PedACR70 at Week 3619
Number of subjects achieving PedACR70 at Week 4817
Number of subjects achieving PedACR70 at Week 6016
Number of subjects achieving PedACR70 at Week 7215
Number of subjects achieving PedACR70 at Week 9614
Number of subjects achieving PedACR70 at Week 12011
Number of subjects achieving PedACR70 at Week 1445
Number of subjects achieving PedACR70- Final Visit17
SecondaryMean Serum Adalimumab Concentration

Blood samples were drawn prior to drug administration. Adalimumab concentrations in serum were determined using a validated enzyme-linked immunosorbent assay (ELISA) method based on a double-antigen technique. Concentrations are reported as micrograms per milliliter (mcg/mL).

Time frame:
Week 2, 4, 8, 16, and 24, and every 12 weeks up to Week 60
Reported as:
Mean · mcg/mL
Mean Serum Adalimumab Concentration
mcg/mLAdalimumab
20 mg dose at Week 25.24 ± 1.74
20 mg dose at Week 45.46 ± 5.18
20 mg dose at Week 86.15 ± 5.88
20 mg dose at Week 165.73 ± 5.26
20 mg dose at Week 245.79 ± 6.51
20 mg dose at Week 367.60 ± 7.58
20 mg dose at Week 487.97 ± 6.69
20 mg dose at Week 6011.4 ± 9.87
40 mg dose at Week 25.03 ± 1.45
40 mg dose at Week 45.63 ± 2.71
40 mg dose at Week 88.66 ± 4.41
40 mg dose at Week 1610.8 ± 6.15
40 mg dose at Week 2411.9 ± 6.80
40 mg dose at Week 3612.6 ± 6.44
40 mg dose at Week 4813.0 ± 8.89
40 mg dose at Week 6013.1 ± 6.73
SecondaryNumber of Subjects Positive for Anti-adalimumab Antibodies (AAA)

Serum samples with adalimumab concentration below 2 mcg/mL were selected for AAA analyses. Samples were considered AAA positive if the measured AAA concentration was above 20 ng/mL. A subject was considered to be AAA positive if the subject had at least one AAA positive sample observed within 30 days following the subject's last adalimumab dose.

Time frame:
Week 24 and Week 60
Reported as:
Number · Participants
Number of Subjects Positive for Anti-adalimumab Antibodies (AAA)
ParticipantsAdalimumab
Number of subjects with AAA by Week 244
Number of subjects with AAA by Week 606

Adverse events

Collected over All adverse events reported from the time of first study drug administration until 70 days following discontinuation of study drug administration were collected.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab—6/25 (24%)25/25 (100%)
Most frequent serious events
Most frequent serious events
EventAdalimumab
pyrexiaGeneral disorders2/25
hepatitis BInfections and infestations1/25
herpes zosterInfections and infestations1/25
pharyngitisInfections and infestations1/25
pneumoniaInfections and infestations1/25
dehydrationMetabolism and nutrition disorders1/25
arthralgiaMusculoskeletal and connective tissue disorders1/25
juvenile arthritisMusculoskeletal and connective tissue disorders1/25
amnesiaNervous system disorders1/25
pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders1/25
Most frequent other events
Showing 10 of 45
Most frequent other events
EventAdalimumab
nasopharyngitisInfections and infestations14/25
upper respiratory tract infectionInfections and infestations14/25
influenzaInfections and infestations8/25
pharyngitisInfections and infestations8/25
gastroenteritisInfections and infestations6/25
urticariaSkin and subcutaneous tissue disorders6/25
iron deficiency anaemiaBlood and lymphatic system disorders5/25
pyrexiaGeneral disorders5/25
hordeolumInfections and infestations5/25
eczemaSkin and subcutaneous tissue disorders5/25

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Adalimumab
<=18 years25
Between 18 and 65 years0
>=65 years0
Age Continuous
Age Continuous(years)Adalimumab
Mean13.0 ± 3.38
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab
Female20
Male5
Region of Enrollment
Region of Enrollment(participants)Adalimumab
Japan25
08

Study locations

12 sites
  • Site Reference ID/Investigator# 47248
    Aichi, Japan
  • Site Reference ID/Investigator# 47253
    Fukuoka, Japan
  • Site Reference ID/Investigator# 47251
    Hyogo, Japan
  • Site Reference ID/Investigator# 47254
    Kagoshima, Japan
  • Site Reference ID/Investigator# 47250
    Kobe, Japan
  • Site Reference ID/Investigator# 47255
    Okinawa, Japan
  • Site Reference ID/Investigator# 7153
    Sendai, Japan
  • Site Reference ID/Investigator# 47249
    Takatsuki, Japan
  • Site Reference ID/Investigator# 47243
    Tokyo, Japan
  • Site Reference ID/Investigator# 47244
    Tokyo, Japan
  • Site Reference ID/Investigator# 47245
    Tokyo, Japan
  • Site Reference ID/Investigator# 47246
    Yokohama, Japan
09

References and documents

Publications

  • Horneff G, Seyger MMB, Arikan D, Kalabic J, Anderson JK, Lazar A, Williams DA, Wang C, Tarzynski-Potempa R, Hyams JS. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. J Pediatr. 2018 Oct;201:166-175.e3. doi: 10.1016/j.jpeds.2018.05.042. Epub 2018 Jul 25. PubMed 30054164 ↗
  • Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, Iwata N, Murata T, Okafuji I, Miyoshi M, Onoe Y, Kawano Y, Kinjo N, Mori M, Mozaffarian N, Kupper H, Santra S, Patel G, Kawai S, Yokota S. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol. 2012 Dec;31(12):1713-21. doi: 10.1007/s10067-012-2082-5. Epub 2012 Oct 2. PubMed 23053683 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Mar 2010 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2008
First posted
Jun 4, 2008
Start
May 2008
Primary completionActual
Mar 2010
CompletionActual
Sep 2011
Results first posted
Apr 1, 2011
Last update
Sep 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00690573
Lead sponsor
Abbott
Collaborators
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Jun 4, 2008
Start date
May 2008
Primary completion
Mar 2010
Completion
Sep 2011
Results posted
Apr 1, 2011
Last update
Sep 10, 2012

Study contacts

Shigeki Hashimoto, PhD
study director · Abbott Japan Co.,Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion